Larvol Delta - BioAge-Initiates-Phase-2-Trial-of-BGE175-to-Treat-COVID19-by-Reversing-Immune-Aging-a-Key-Cause-of-Morbidity-and-Mortality-in-Older-Patients

asapiprant (BGE-175) - BioAge, Shionogi

https://www.businesswire.com/news/home/20210322005146/en/BioAge-Initiates-Phase-2-Trial-of-BGE-175-to-Treat-COVID-19-by-Reversing-Immune-Aging-a-Key-Cause-of-Morbidity-and-Mortality-in-Older-Patients

Mar 22, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next